10.61
+0.07(+0.66%)
Currency In USD
| Previous Close | 10.54 |
| Open | 10.57 |
| Day High | 10.94 |
| Day Low | 10.57 |
| 52-Week High | 17.43 |
| 52-Week Low | 5.6 |
| Volume | 1.65M |
| Average Volume | 3.35M |
| Market Cap | 791.96M |
| PE | 13.6 |
| EPS | 0.78 |
| Moving Average 50 Days | 12.18 |
| Moving Average 200 Days | 11.11 |
| Change | 0.07 |
If you invested $1000 in CorMedix Inc. (CRMD) 10 years ago, it would be worth $825.68 as of October 15, 2025 at a share price of $10.61. Whereas If you bought $1000 worth of CorMedix Inc. (CRMD) shares 5 years ago, it would be worth $1,798.31 as of October 15, 2025 at a share price of $10.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
GlobeNewswire Inc.
Sep 29, 2025 12:30 PM GMT
- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant - - Topline Results from ReSPECT Study Expected in 2Q 2026 - BERKELEY HEIGHTS, N.J., Sep
CorMedix Announces Strategic Minority Investment in Talphera
GlobeNewswire Inc.
Sep 08, 2025 12:30 PM GMT
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today ann
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
GlobeNewswire Inc.
Sep 02, 2025 11:30 AM GMT
- Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential - - Revised guidance of pro form